[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640753":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":24,"responsibleParty":34,"collaborators":38,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":24,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":24,"enrollmentInfo":74,"targetDuration":24,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":87,"whyStopped":24,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":24},{"fullName":5,"class":6},"Shanghai Public Health Clinical Center","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"2HPMZ\u002F2HPM","EXPERIMENTAL","8 weeks of daily isoniazid, rifapentine, moxifloxacin and pyrazinamide, followed by 9 weeks of daily isoniazid, rifapentine and moxifloxacin.",[13],"Drug: 2HPMZ\u002F2HPM",{"label":15,"type":16,"description":15,"interventionNames":17},"2HRZE\u002F4HR","ACTIVE_COMPARATOR",[18],"Drug: 2HRZE\u002F4HR",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","8 weeks of daily isoniazid, rifapentine, moxifloxacin and pyrazinamide, followed by 9 weeks of daily isoniazid, rifapentine and moxifloxacin",[9],null,{"type":21,"name":15,"description":26,"armGroupLabels":27,"otherNames":24},"2 months of isoniazid, rifampin, pyrazinamide, and ethambutol followed by 4 months of isoniazid and rifampin",[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":24,"email":33},"Yinzhong Shen, Professor","CONTACT","+86 18916113951","Shenyinzhong@shphc.org.cn",{"type":35,"investigatorFullName":36,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Yinzhong Shen","Professor",[39,42,45,47,49,51,53,55,57,59,61,63],{"name":40,"class":41},"Beijing Ditan Hospital","OTHER",{"name":43,"class":44},"Guangzhou eighth People's Hospital ,Guangzhou Medilcal University","UNKNOWN",{"name":46,"class":41},"The Second Hospital of Nanjing Medical University",{"name":48,"class":41},"Chengdu Public Health Clinical Center",{"name":50,"class":6},"The Third People's Hospital of Yunnan Province",{"name":52,"class":41},"Meng Chao Hepatobiliary Hospital of Fujian Medical University",{"name":54,"class":41},"Peking Union Medical College Hospital",{"name":56,"class":41},"Beijing YouAn Hospital",{"name":58,"class":41},"The First Affiliated Hospital of Zhengzhou University",{"name":60,"class":44},"Guiyang Public Health Clinical Center",{"name":62,"class":41},"Chongqing Public Health Medical Center",{"name":64,"class":44},"Chest Hospital of Guangxi Zhuang Autonomous Region","100640753","short-course-regimens-for-ds-ptb-in-aids-patients-100640753",false,"NCT07608172","Short-Course Regimens for DS-PTB in AIDS Patients","A Validation Study of Short-Course Regimens for Drug-Susceptible Pulmonary Tuberculosis in AIDS Patients","Inclusion Criteria:\n\n* Age ≥ 18 years, able to understand and sign the informed consent form.\n* Confirmed HIV infection.\n* Baseline CD4+ T-lymphocyte count \\\u003C 100 cells\u002FμL.\n* Confirmed active pulmonary tuberculosis.\n* Agree to receive antituberculosis treatment and antiretroviral therapy during the study period.\n\nExclusion Criteria:\n\n* Known or suspected resistance to any of the drugs in the regimen, including rifapentine, moxifloxacin, rifampicin, isoniazid, ethambutol, and pyrazinamide.\n* Body weight \\\u003C 40 kg.\n* Received the current tuberculosis treatment for more than 7 days.\n* Complicated with tuberculous meningitis or other severe forms of tuberculosis.\n* Severe liver dysfunction (ALT or AST \\> 5 times the upper limit of normal, ULN). - - Severe renal dysfunction (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²).\n* Baseline electrocardiogram (ECG) showing QTc interval \\> 500 ms.\n* Pregnant or lactating women.\n* Presence of other conditions deemed inappropriate for study participation by the investigators.","ALL","18 Years",{"count":75,"type":76},148,"ESTIMATED","INTERVENTIONAL",[79],"NA","This study adopts a multicenter, open-label, randomized controlled design, conducted across key designated AIDS diagnosis and treatment hospitals nationwide. It aims to compare the efficacy and safety of the 2HPMZ\u002F2HPM regimen versus the 2HRZE\u002F4HR regimen in treating HIV-associated drug-susceptible pulmonary tuberculosis (DS-TB) among patients with a CD4+ T-cell count \\\u003C 100 cells\u002FμL. A total of 148 participants will be enrolled and randomized 1:1 into two groups: 74 cases in the 2HPMZ\u002F2HPM group and 74 cases in the 2HRZE\u002F4HR group.",[82,83],"Tuberculosis in HIV-infected Individuals","Drug Susceptible Pulmonary Tuberculosis",[85,86,9],"Drug susceptible pulmonary tuberculosis","HIV-infected individuals","NOT_YET_RECRUITING","2026-05-24",{"date":90,"type":91},"2026-05-27","ACTUAL",{"date":93,"type":76},"2026-05-25",{"date":95,"type":76},"2028-12-31",{"name":5,"class":6}]